Literature DB >> 3969958

Immunoglobulins in certain CNS disorders: a study of CSF Ig classes G, A, M, D, and E concentrations.

R Prasad.   

Abstract

Concentrations of cerebrospinal fluid (CSF) Ig classes G, A, M, D, and E have been reported in various neurologic disorders, viz, aseptic meningitis, multiple sclerosis, benign tumor, malignant tumor, and hydrocephalus. In aseptic meningitis, IgG and IgM were found to be either normal or elevated, whereas concentrations of IgA, IgD, and IgE were normal. Multiple sclerosis patients had IgG, IgA, and IgM, either normal or elevated, but IgD and IgE were on the lower end of the normal. Malignant tumor patients had elevated concentrations of IgG, IgA, IgM, and IgE, but their IgD was on the lower end of the normal. In benign tumor population IgA and IgE, and in hydrocephalus IgG and IgA, were found to be elevated in most of the patients. On statistical analysis, significant differences were observed between the means of the normal group and that of the patients' group for all the five immunoglobulins. By linear regression, a statistical relationship was observed between IgA - IgG, IgM - IgG, IgA - IgM and IgA + IgM - IgG in these neurologic disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3969958     DOI: 10.1093/ajcp/83.2.190

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Inflammation is correlated with severity and outcome of cerebral venous thrombosis.

Authors:  Liyan Wang; Jiangang Duan; Tingting Bian; Ran Meng; Longfei Wu; Zhen Zhang; Xuxiang Zhang; Chunxiu Wang; Xunming Ji
Journal:  J Neuroinflammation       Date:  2018-11-26       Impact factor: 8.322

2.  A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.

Authors:  Andrew Eisen; Benjamin M Greenberg; James D Bowen; Douglas L Arnold; Anthony O Caggiano
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.